🔴 GT Biopharma is trading 6.1% down today after convertible financing raises dilution concerns

GT Biopharma is trading 6.1% down at $8.45 after investors digested its $7.45 million private placement of convertible preferred stock and warrants.

• Securities convert at $6.10 per share, include equivalent-share warrants, and carry greenshoe rights up to $30 million, creating potential future dilution.
• Shares closed at $9.00 on September 15 after a 22.61% drop, following gains of 35.08% on September 14 and 39.32% on September 11.
• Broader biotech weakness adds pressure, but the financing is the clearest company-specific catalyst.